Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin

The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed sulphonylureas (SUs), which are metabolized by cytochrome P450 2C9 (abbreviated as CYP2C9). SUs are a type of oral anti-diabetic compound which inhibit ATP-sensitive potassium channels, thus inducing gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuautle-Rodríguez, Patricia, Rodríguez-Rivera, Nidia, De Andrés, Fernando, Castillo-Nájera, Fernando, Llerena, Adrián, Molina-Guarneros, Juan Arcadio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489535/
https://www.ncbi.nlm.nih.gov/pubmed/31086662
http://dx.doi.org/10.3892/br.2019.1204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489535/
https://www.ncbi.nlm.nih.gov/pubmed/31086662
http://dx.doi.org/10.3892/br.2019.1204

Ejemplares similares